Cancer Pain - Pipeline Review, H2 2012


#138066

125pages

Global Markets Direct

$ 2000

In Stock


Cancer Pain Pipeline Review, H2 2012

Global Markets Directs, 'Cancer Pain Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cancer Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Pain. 

Cancer Pain Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Cancer Pain.
  • A review of the Cancer Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Cancer Pain pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Cancer Pain.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. 
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Cancer Pain Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Cancer Pain 11
Cancer Pain Therapeutics under Development by Companies 13
Cancer Pain Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Cancer Pain Therapeutics Products under Development by Companies 22
Cancer Pain Therapeutics Products under Investigation by Universities/Institutes 23
Companies Involved in Cancer Pain Therapeutics Development 24
Johnson & Johnson 24
BioDelivery Sciences International, Inc. 25
Daiichi Sankyo Company, Ltd 26
Sangamo BioSciences, Inc. 27
Ipsen S.A. 28
A.P. Pharma, Inc. 29
AcelRx Pharmaceuticals, Inc. 30
Nippon Kayaku Co., Ltd. 31
Nippon Shinyaku Co., Ltd. 32
Taiho Pharmaceutical Co., Ltd. 33
GW Pharmaceuticals plc 34
IntelGenx Technologies Corp. 35
Benitec Ltd. 36
NovaDel Pharma, Inc. 37
Diamyd Medical AB 38
ProStrakan Group plc 39
Orexo AB 40
BioAlliance Pharma SA 41
Labtec GmbH 42
AngioChem Inc. 43
WEX Pharmaceuticals Inc. 44
QRxPharma Limited 45
APEIRON Biologics AG 46
Winston Pharmaceuticals, Inc. 47
Afferent Pharmaceuticals, Inc. 48
Cancer Pain Therapeutics Assessment 49
Assessment by Monotherapy Products 49
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
fentanyl citrate - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
BIM-46187 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Sativex - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
fentanyl citrate - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
tapentadol hydrochloride ER - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
fentanyl citrate - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
buprenorphine hydrochloride - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
fentanyl citrate - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Tectin - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
fentanyl citrate - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ZFP TFs For Neuropathic Pain - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
morphine sulfate+oxycodone hydrochloride CR - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
sufentanil - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
fulranumab - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
acetaminophen - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
sufentanil - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
hydromorphone hydrochloride - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
NP-2 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
ANG-2002 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
resiniferatoxin - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
ketamine hydrochloride - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
P2X3 Targeted Program - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
fentanyl citrate - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
methadone hydrochloride - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
tramadol hydrochloride - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
fentanyl citrate - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
OX-27 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
zucapsaicin - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
DEX-IN - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
THA-901 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
ddRNAi Program For Cancer-Associated Pain - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
APN-601 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
leconotide - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
IPTRK-3 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
AF-353 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
INT-0028 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Cancer Pain Therapeutics Drug Profile Updates 103
Cancer Pain Therapeutics Discontinued Products 116
Cancer Pain Therapeutics - Dormant Products 117
Cancer Pain Product Development Milestones 118
Featured News & Press Releases 118
Jul 11, 2012: Taiho And Teikoku Form Business Partnership For Pain Reliever OVF 118
Jul 03, 2012: Diamyd Medical Reports Results From Phase II Study Of NP2 Enkephalin In Cancer Pain 118
May 25, 2012: Orexo Receives 3.3m Milestone Payment From ProStrakan 119
May 22, 2012: Diamyd Medical Completes Recruitment In Phase II Cancer Pain Study 119
May 22, 2012: GW Pharma Initiates Third Phase III Sativex Clinical Trial For Cancer Pain 120
Apr 23, 2012: GW Pharma And Otsuka Announce Publication Of Phase IIb Pain Trial Results Of Sativex In Journal Of Pain 121
Apr 16, 2012: GW Pharma Earns 11.9m Milestone Payment 121
Apr 11, 2012: AcelRx Pharma Receives Two Notices Of Allowance For Small-Volume Oral Transmucosal Dosage Forms 121
Mar 23, 2012: Daiichi Sankyo To Develop Narcotic Analgesic Hydromorphone Hydrochloride In Japan 122
Mar 14, 2012: Federal Court Grants Request Of BioDelivery Sciences For Stay Of MonoSol Litigation 123

Appendix 124
Methodology 124
Coverage 124
Secondary Research 124
Primary Research 124
Expert Panel Validation 124
Contact Us 125
Disclaimer 125

Number of Products Under Development for Cancer Pain, H2 2012 11
Products under Development for Cancer Pain Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 14
Number of Products under Development by Companies, H2 2012 (Contd..1) 15
Number of Products under Development by Companies, H2 2012 (Contd..2) 16
Number of Products under Investigation by Universities/Institutes, H2 2012 17
Comparative Analysis by Late Stage Development, H2 2012 18
Comparative Analysis by Mid Clinical Stage Development, H2 2012 19
Comparative Analysis by Early Clinical Stage Development, H2 2012 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 21
Products under Development by Companies, H2 2012 22
Products under Investigation by Universities/Institutes, H2 2012 23
Johnson & Johnson, H2 2012 24
BioDelivery Sciences International, Inc., H2 2012 25
Daiichi Sankyo Company, Ltd, H2 2012 26
Sangamo BioSciences, Inc., H2 2012 27
Ipsen S.A., H2 2012 28
A.P. Pharma, Inc., H2 2012 29
AcelRx Pharmaceuticals, Inc., H2 2012 30
Nippon Kayaku Co., Ltd., H2 2012 31
Nippon Shinyaku Co., Ltd., H2 2012 32
Taiho Pharmaceutical Co., Ltd., H2 2012 33
GW Pharmaceuticals plc, H2 2012 34
IntelGenx Technologies Corp., H2 2012 35
Benitec Ltd., H2 2012 36
NovaDel Pharma, Inc., H2 2012 37
Diamyd Medical AB, H2 2012 38
ProStrakan Group plc, H2 2012 39
Orexo AB, H2 2012 40
BioAlliance Pharma SA, H2 2012 41
Labtec GmbH, H2 2012 42
AngioChem Inc., H2 2012 43
WEX Pharmaceuticals Inc., H2 2012 44
QRxPharma Limited, H2 2012 45
APEIRON Biologics AG, H2 2012 46
Winston Pharmaceuticals, Inc., H2 2012 47
Afferent Pharmaceuticals, Inc., H2 2012 48
Assessment by Monotherapy Products, H2 2012 49
Assessment by Stage and Route of Administration, H2 2012 51
Assessment by Stage and Molecule Type, H2 2012 53
Cancer Pain Therapeutics Drug Profile Updates 103
Cancer Pain Therapeutics Discontinued Products 116
Cancer Pain Therapeutics Dormant Products 117
Number of Products under Development for Cancer Pain, H2 2012 11
Products under Development for Cancer Pain Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 17
Late Stage Products, H2 2012 18
Mid Clinical Stage Products, H2 2012 19
Early Clinical Stage Products, H2 2012 20
Discovery and Pre-Clinical Stage Products, H2 2012 21
Assessment by Monotherapy Products, H2 2012 49
Assessment by Route of Administration, H2 2012 50
Assessment by Stage and Route of Administration, H2 2012 51
Assessment by Molecule Type, H2 2012 52
Assessment by Stage and Molecule Type, H2 2012 53